Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

TipRanks

Sat, January 10, 2026 astatine 8:35 AM CST 1 min read

“We are encouraged by the maturation successful Q4 2025, driven successful peculiar by the momentum successful our Acute Care franchise with ZYNRELEF and APONVIE,” said Craig Collard, CEO. “In summation to our gross growth, we are highly pleased with the continued advancement made crossed each aspects of our concern passim the past year.” Preliminary Q4 and FY25 Updates: Net gross of astir $40.5M for the 3 months ended December 31. ZYNRELEF nett gross of astir $12.5M for the 3 months ended December 31. APONVIE nett gross of astir $3.8M for the 3 months ended December 31. CINVANTI nett gross of astir $22.9M for the 3 months ended December 31. SUSTOL nett gross of astir $1.3M for the 3 months ended December 31. Net gross of astir $154.9M for FY25. ZYNRELEF delivered the largest quarter-over-quarter gross summation wrong the portfolio successful Q4.

• Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions

• Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential